NYSEAMERICAN:CVRS - Corindus Vascular Robotics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.27 +0.01 (+0.79 %)
(As of 12/13/2018 10:03 AM ET)
Previous Close$1.26
Today's Range$1.2637 - $1.27
52-Week Range$0.70 - $1.65
Volume8,263 shs
Average Volume918,443 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Corindus Vascular Robotics, Inc. designs, manufactures, and sells robotic-assisted precision vascular systems for use in interventional vascular procedures in the United States and internationally. The company offers CorPath system, a medical device with robotic-assisted precision for radial, coronary, and peripheral procedures. Its CorPath system facilitates stent positioning for PCI procedures by allowing a physician to measure, manipulate, and advance devices with robotic precision; and CorPath GRX system enables the precise robotic-assisted control of coronary guide catheters, guidewires, and balloon/stent devices from the safety of a radiation-shielded interventional cockpit. The company sells its products through direct sales force, as well as through distributor and partnership relationships. It serves vascular, coronary, peripheral vascular, neurointerventional, and structural heart markets. Corindus Vascular Robotics, Inc. is headquartered in Waltham, Massachusetts.

Receive CVRS News and Ratings via Email

Sign-up to receive the latest news and ratings for CVRS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Medical Appliances & Equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:CVRS
Previous SymbolNYSEMKT:CVRS
CUSIPN/A
Phone+1-508-6533335

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees106
Outstanding Shares191,320,000
Market Cap$0.00
OptionableNot Optionable

Corindus Vascular Robotics (NYSEAMERICAN:CVRS) Frequently Asked Questions

What is Corindus Vascular Robotics' stock symbol?

Corindus Vascular Robotics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CVRS."

How were Corindus Vascular Robotics' earnings last quarter?

Corindus Vascular Robotics Inc (NYSEAMERICAN:CVRS) posted its quarterly earnings data on Tuesday, November, 6th. The medical equipment provider reported ($0.04) EPS for the quarter, beating the Zacks' consensus estimate of ($0.05) by $0.01. The medical equipment provider earned $2.96 million during the quarter, compared to analysts' expectations of $3.20 million. View Corindus Vascular Robotics' Earnings History.

When is Corindus Vascular Robotics' next earnings date?

Corindus Vascular Robotics is scheduled to release their next quarterly earnings announcement on Wednesday, March 13th 2019. View Earnings Estimates for Corindus Vascular Robotics.

What price target have analysts set for CVRS?

3 brokers have issued 1 year price targets for Corindus Vascular Robotics' shares. Their predictions range from $1.00 to $2.00. On average, they expect Corindus Vascular Robotics' share price to reach $1.6667 in the next twelve months. This suggests a possible upside of 31.2% from the stock's current price. View Analyst Price Targets for Corindus Vascular Robotics.

What is the consensus analysts' recommendation for Corindus Vascular Robotics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corindus Vascular Robotics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Corindus Vascular Robotics.

Has Corindus Vascular Robotics been receiving favorable news coverage?

News stories about CVRS stock have trended very positive recently, according to InfoTrie. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Corindus Vascular Robotics earned a daily sentiment score of 4.0 on InfoTrie's scale. They also gave media headlines about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the near term.

Are investors shorting Corindus Vascular Robotics?

Corindus Vascular Robotics saw a decrease in short interest in November. As of November 30th, there was short interest totalling 12,759,588 shares, a decrease of 1.0% from the November 15th total of 12,885,327 shares. Based on an average daily volume of 314,918 shares, the days-to-cover ratio is presently 40.5 days. Currently, 15.2% of the shares of the company are short sold. View Corindus Vascular Robotics' Current Options Chain.

Who are some of Corindus Vascular Robotics' key competitors?

Who are Corindus Vascular Robotics' key executives?

Corindus Vascular Robotics' management team includes the folowing people:
  • Mr. Mark J. Toland, CEO, Pres & Director (Age 48)
  • Mr. David W. Long, CFO, Sr. VP, Sec. & Treasurer (Age 48)
  • Mr. Tal Wenderow, Co-Founder and Exec. VP of International & Bus. Devel.
  • Mr. Douglas Teany, Chief Operating Officer
  • Ms. Nora Dutta, VP of HR

Who are Corindus Vascular Robotics' major shareholders?

Corindus Vascular Robotics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (1.96%) and Citadel Advisors LLC (0.06%). Company insiders that own Corindus Vascular Robotics stock include Healthcor Management, LP, Louis A Cannon and Philips Nv Koninklijke. View Institutional Ownership Trends for Corindus Vascular Robotics.

Which major investors are selling Corindus Vascular Robotics stock?

CVRS stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. View Insider Buying and Selling for Corindus Vascular Robotics.

Which major investors are buying Corindus Vascular Robotics stock?

CVRS stock was purchased by a variety of institutional investors in the last quarter, including Citadel Advisors LLC. Company insiders that have bought Corindus Vascular Robotics stock in the last two years include Healthcor Management, LP and Louis A Cannon. View Insider Buying and Selling for Corindus Vascular Robotics.

How do I buy shares of Corindus Vascular Robotics?

Shares of CVRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Corindus Vascular Robotics' stock price today?

One share of CVRS stock can currently be purchased for approximately $1.27.

What is Corindus Vascular Robotics' official website?

The official website for Corindus Vascular Robotics is http://www.corindus.com/.

How can I contact Corindus Vascular Robotics?

Corindus Vascular Robotics' mailing address is 309 Waverley Oaks Rd Ste 105, WALTHAM, MA 02452-8451, United States. The medical equipment provider can be reached via phone at +1-508-6533335.


MarketBeat Community Rating for Corindus Vascular Robotics (NYSEAMERICAN CVRS)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  266 (Vote Outperform)
Underperform Votes:  333 (Vote Underperform)
Total Votes:  599
MarketBeat's community ratings are surveys of what our community members think about Corindus Vascular Robotics and other stocks. Vote "Outperform" if you believe CVRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CVRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel